Keywords
Acute Coronary Syndrome; Anticoagulants; Blood Platelets; Cardiology; Coronary Artery Disease; Embolism and Thrombosis
Research group(s)
- European Platelet Academy
Members: - I-COMET International Cardiovascular and Cardiometabolic Research Team
Head: Jolanta Siller-Matula
Research Area: We are an international and intercontinental team of scientists with diverse backgrounds in cardiovascular diseases. We have experience in clinical and translational research, basic science, bioinformatics and mathematics. Although our team members are at different stages of their professional career, we share a passion for state-of-the art scientific approach to answering burning questions aiming at improving patients care.
Members: - ICPC - International Clopidogrel Pharmacogenomics Consortium
Members:
Research interests
Jolanta Siller-Matula heads up an international research group called I-COMET (International Cardiovascular and Cardiometabolic Research Team), which is currently focusing on research into personalised therapies and diagnostic biomarkers for cardiovascular and cardiometabolic diseases. Siller-Matula conducts interdisciplinary research in the fields of interventional cardiology, haemostaseology and clinical pharmacology. She has published over 180 peer-reviewed papers (70 of them as first or last author), which, according to Scopus, have been cited over 5,000 times (Hirsch index 46) and has received more than 150 invitations to give talks at national and international meetings. Her research in the field of antithrombotic therapies for the treatment of patients following coronary stent implantation has been cited in European and American guidelines. She holds a position as assistant editor in Circulation Cardiovascular Intervention and is a visiting professor at the Medical University of Warsaw.
Techniques, methods & infrastructure
Clinical studies, platelet reactivity testing, genetic testing, statistical modeling, meta-analysis, path analysis.
Selected publications
- Siller-Matula, J.M., 2012. Hemorrhagic Complications Associated With Aspirin. JAMA, 307(21). Available at: http://dx.doi.org/10.1001/jama.2012.6152.
- Siller-Matula, J.M. et al., 2008. Calcium-Channel Blockers Reduce the Antiplatelet Effect of Clopidogrel. Journal of the American College of Cardiology, 52(19), pp.1557-1563. Available at: http://dx.doi.org/10.1016/j.jacc.2008.07.055.
- Siller-Matula, J.M. et al., 2009. Effects of pantoprazole and esomeprazole on platelet inhibition by clopidogrel. American Heart Journal, 157(1), pp.148.e1-148.e5. Available at: http://dx.doi.org/10.1016/j.ahj.2008.09.017.
- Tantry, U.S. et al., 2013. Consensus and Update on the Definition of On-Treatment Platelet Reactivity to Adenosine Diphosphate Associated With Ischemia and Bleeding. Journal of the American College of Cardiology, 62(24), pp.2261-2273. Available at: http://dx.doi.org/10.1016/j.jacc.2013.07.101.
- Siller-Matula, J.M. et al., 2012. ARC15105 Is a Potent Antagonist of Von Willebrand Factor Mediated Platelet Activation and Adhesion. Arteriosclerosis, Thrombosis, and Vascular Biology, 32(4), pp.902-909. Available at: http://dx.doi.org/10.1161/ATVBAHA.111.237529.